Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE Due to ubiquitous HRAS gene expression, CS affects multiple organ systems and individuals are predisposed to cancer. 31222966

2019

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The co-delivery of anti-p21Ras scFv by CIK cells and KGHV500 could increase the anti-tumor effect and safety, and possess considerable advantages for the treatment of Ras-related cancer. 30796510

2019

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE HRAS-driven cancer cells are vulnerable to TRPML1 inhibition. 30787043

2019

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Both cell subsets rapidly progressed to cancer upon introduction of constitutively active versions of either HRAS or BRAF. 30401712

2019

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE The results suggest that ancestral exposure to alcohol can have enduring effects that impact epigenetic processes such as DNA methylation that controls expression of genes that drive cancer development such as HRAS and TP53. 28799801

2017

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Ras mutations and overexpression of the Ras protein, p21Ras, are main causes of cancer development and progression, which has made the Ras gene and p21Ras important targets for therapy of Ras-driven cancers. 27834948

2017

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Preoperative RAS mutation detection in thyroid nodules carries a substantial risk of cancer with a greater risk associated with HRAS and NRAS. 27863786

2017

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer. 27195699

2016

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. 25805818

2015

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Our results show that HRAS mutations in cancer activate the RAS and mTOR pathways which might serve as a therapeutic option for patients with HRAS mutant tumors. 26544513

2015

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE HRAS is a proto-oncogene and has potential to cause cancer in several organs including the bladder. 27352265

2015

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE Oncogenic HRAS in HNSCC promotes activation of ERK signaling, which in turn mediates cetuximab resistance through a specific gene expression signature.Clin Cancer Res; 20(11); 2933-46.©2014 AACR. 24696319

2014

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Although somatic HRAS mutations have been described in many cancers, germline mutations cause Costello syndrome (CS), a congenital disorder associated with predisposition to malignancy. 24259709

2013

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Abnormal methylation of the HRAS gene may be an early event during urocystic tumorigenesis and may be further used as a cancer biomarker in bladder tissue for early diagnosis and a potential therapeutic target. 22707223

2012

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). 21622730

2011

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Over the last century, the history of cancer epidemiology evolved in different stages and concepts from occupational observational studies beginning in the 18th century, in vitro and in vivo experimental analyses and cancer gene analyses, such as Ha-ras or TP53. 21791238

2011

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE In addition to identifying previously known HNSCC genes (TP53, CDKN2A, PTEN, PIK3CA, and HRAS), our analysis revealed many genes not previously implicated in this malignancy. 21798893

2011

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE G4-DNA formation in the HRAS promoter and rational design of decoy oligonucleotides for cancer therapy. 21931711

2011

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Here, we aimed to characterize common and unique miRNAs regulated by transcriptional regulators such as oncogenic HRAS, c-Jun and E2F family members (E2F1≈E2F6) in the human cancer cell lines A549 and HeLa. 20878133

2010

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE It can be concluded that the organophosphorous pesticides parathion and malathion induced malignant transformation of breast cells through genomic instability altering p53 and c-Ha-ras, considered pivotal to cancer process. 19787260

2009

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Mutations of the KRAS2 gene are one of the most common genetic aberrations in this cancer. 19815696

2009

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE At multivariate analysis, cancer-related survival was associated with Dukes' stage (p<0.0001), CEA level (p=0.02), and mutant circulating KRAS2 (p=0.01). 17177160

2007

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Pancreatic ductal adenocarcinomas exhibit the highest incidence of activating KRAS (Ki-Ras) mutations observed in any human cancer. 16598499

2006

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE An activating point mutation in codon 12 of the HRAS gene was the first somatic point mutation identified in a human cancer and established the role of somatic mutations as the common driver of oncogenesis. 16969076

2006

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE To gain an understanding of the relationship between constitutional HRAS mutations and malignancy, HRAS was sequenced in an advanced biphasic rhabdomyosarcoma/fibrosarcoma from an individual with a 34G --> A mutation. 16372351

2006